Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Monotherapy, Dose-Escalation, Phase 1 Clinical Trial of NB02 (Posseltinib) in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

NCT07114367 is registered in ClinicalTrials.gov with NOBO Medicine as lead sponsor.

NCT NCT07114367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07114367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Monotherapy, Dose-Escalation, Phase 1 Clinical Trial of NB02 (Posseltinib) in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma
Lead sponsor
NOBO Medicine
Phase
Phase 1
Overall status
Recruiting
Start date
December 2, 2025
Completion date
December 31, 2027
Enrollment
9 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

non hodgkin lymphoma (nhl)